LYON, France, December 19, 2019-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that Focal One data has been accepted for publication in the ...

LYON, France, March 4, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by ...

LYON, France, November 30, 2022-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French ...

Recently, new knowledge has been acquired that will influence therapeutic strategies. In particular, two novel techniques will improve medical treatment over the next few years and even produce a ...

LYON, France, February 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) ...

The relationship between these two endometrial disorders seems to have gone in a full circle; at the beginning of the 20th Century only one pathological definition (adenomyoma) was utilized to ...

Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis LYON, France,December 19, 2019-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ...